Top Markets
Coin of the day
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Helyezés a részvények között #170
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily... Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
Részvényárfolyam
$519.38
Utolsó szinkronizálás: 2026-09-14
Piaci kapitalizáció
$131.82B
Változás (1 nap)
0.76%
Változás (1 év)
32.09%
Ország
US
Kereskedés Vertex Pharmaceuticals Incorporated (VRTX)

Kategória

Bevétel a(z) Vertex Pharmaceuticals Incorporated (VRTX) részvényhez
Bevétel ekkor: Jun 2026 TTM: $12.62B
Vertex Pharmaceuticals Incorporated legfrissebb pénzügyi jelentései szerint a vállalat jelenlegi árbevétele (TTM) $12.62B. 2024 évben a vállalat $11.02B árbevételt ért el, amely növekedés a 2023 évben elért $9.87B árbevételhez képest. Az árbevétel az a teljes összeg, amit a vállalat termékek vagy szolgáltatások eladásából generál. A nyereséggel ellentétben ebből nem vonódnak le költségek.
Vertex Pharmaceuticals Incorporated bevételtörténete 2000 és 2026 között
Bevétel az év végén
Év Bevétel Változtassa meg
2026 (TTM) $12.62B 5.19%
2025 $12.00B 8.90%
2024 $11.02B 11.66%
2023 $9.87B 10.51%
2022 $8.93B 17.91%
2021 $7.57B 22.06%
2020 $6.21B 49.07%
2019 $4.16B 36.59%
2018 $3.05B 22.46%
2017 $2.49B 46.20%
2016 $1.70B 64.89%
2015 $1.03B 77.86%
2014 $580.42M -52.11%
2013 $1.21B -20.63%
2012 $1.53B 8.25%
2011 $1.41B 883.91%
2010 $143.37M 40.49%
2009 $102.05M -41.85%
2008 $175.50M -11.81%
2007 $199.01M -8.02%
2006 $216.36M 34.47%
2005 $160.89M 56.63%
2004 $102.72M 48.56%
2003 $69.14M -57.08%
2002 $161.09M -3.82%
2001 $167.49M 114.38%
2000 $78.13M 0.00%
Hasonló cégek vagy versenytársak bevétele
Vállalat Bevétel Bevételkülönbség Ország
$6.02B -52.30%
NL
$15.74B 24.71%
AU
$2.23B -82.35%
US
- -
CH
$10.11B -19.91%
BE